Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.
Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.
Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.
Bausch + Lomb has launched Alaway® Preservative Free antihistamine eye drops, the first FDA-approved OTC option for relieving itchy eyes from allergies. This product is now rolling out in major U.S. retailers, including Walgreens and CVS, priced at $14.99 for a 10-day supply. The eye drops offer fast relief within minutes, lasting up to 12 hours, and are especially beneficial for those who find oral medications insufficient. This innovation targets the significant market of allergy sufferers, estimated to affect 80% of individuals with allergies.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a $100 million debt reduction through the redemption of senior secured notes, utilizing cash generated from operations. This move is part of the company's strategy to recover from the COVID-19 pandemic and enhance shareholder value, particularly in view of a planned spinoff of Bausch + Lomb. The redemption of the 7.00% Senior Secured Notes due 2024 is scheduled for March 24, 2021. Bausch Health aims to strengthen its financial position by reducing leverage.
Bausch Health Companies (NYSE/TSX: BHC) announced the opening of the application period for its 2021 Salix Gastrointestinal Health Scholars Program.
This initiative, now in its second year, will award scholarships of up to $10,000 to 10 students living with gastrointestinal (GI) diseases. To apply, students must submit an essay detailing their GI condition's impact on their life. Applications are open until May 31, 2021, with winners to be announced in July 2021.
The program is funded through the Bausch Foundation, dedicated to health care education and patient support.
Bausch Health Companies (NYSE: BHC) announced participation in three investor conferences in March 2021. Key executives, including Chairman Joseph C. Papa and CFO Paul S. Herendeen, will represent the company at:
- Cowen & Co. Health Care Conference on March 1 at 11:00 a.m. ET
- J.P. Morgan Global High Yield & Leveraged Finance Conference on March 3 at 8:30 a.m. ET
- Barclays Global Healthcare Conference on March 9 at 2:25 p.m. ET
Live webcasts will be available on Bausch Health's Investor Relations page.
Bausch Health Companies Inc. (NYSE/TSX: BHC) responded to Icahn Capital LP's Schedule 13D filing, emphasizing their commitment to enhancing shareholder value through open communication. The company plans to spin off Bausch + Lomb to unlock additional value. Bausch Health reported a strong end to 2020, exceeding $2.2 billion in revenue and delivering robust adjusted EBITDA and cash flow. The firm remains focused on its COVID-19 recovery plan and aims to improve EBITDA and working capital while reducing leverage.
Bausch Health Companies Inc. announced that VYZULTA® (latanoprostene bunod ophthalmic solution, 0.024%) has received regulatory approval from South Korea's Ministry of Food and Drug Safety. VYZULTA is designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is now approved in nine markets, including the U.S., Canada, and Mexico. Thomas J. Appio emphasizes the company's commitment to securing additional global approvals for innovative eye health treatments.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched its 2021 Aspire Higher scholarship program, which awards scholarships of up to $10,000 to nine students who have experienced dermatologic conditions. Since its inception in 2013, the program has provided $738,000 to 51 students. Applicants can submit their applications until May 31, 2021, with winners announced in July 2021. The initiative aims to support students managing the challenges of education alongside skin conditions during the pandemic, highlighting the commitment of Bausch Health to enhance educational opportunities for affected students.
Bausch Health (BHC) and Prevent Blindness are launching a year-long video series during AMD Awareness Month to raise awareness about Age-Related Macular Degeneration (AMD), affecting around 16 million Americans. This marks the sixth consecutive year of their collaboration. The campaign will feature real-life stories of individuals managing AMD and will include a social media donation initiative, contributing $1 for each share or like on relevant Facebook posts, up to $50,000. The initiative aims to educate the public on AMD while encouraging eye examinations.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its fourth-quarter and full-year 2020 financial results on February 24, 2021. The company will hold a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can access the call through the company's Investor Relations section on its website, where all related materials will be available prior to the call.
Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), announced on January 21, 2021, that its LUMIFY® redness reliever eye drops received approval from South Korea's Ministry of Food and Drug Safety. This adds to LUMIFY's global presence, following its success in the U.S. where it holds a 40% market share among redness relievers. LUMIFY is expected to be available in South Korea in the second half of 2021, with additional regulatory submissions ongoing in multiple countries.
